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Emery-Dreifuss muscular dystrophyenes encoding A-type lamins and emerin cause cardiomyopathy and muscular
dystrophy. We previously showed activation of the extracellular signal-regulated kinase (ERK) branch of the
mitogen-activated protein kinase (MAPK) cascade in hearts of mice with mutations in these genes. Here, we
tested the hypothesis that reducing A-type lamins and emerin in cultured cells activate ERK signaling.
Methods: We used siRNA to knockdown A-type lamins and emerin in HeLa and C2C12 cells. Activation of
ERK was assessed by immunoblotting and immunoﬂuorescence microscopy with antibodies against
phosphorylated protein and by using real-time RT-PCR to measure RNAs encoded by genes for transcription
factors stimulated by ERK. Results: Knockdown of A-type lamins and emerin in HeLa and C2C12 stimulated
phosphorylation and nuclear translocation of ERK as well as activation of genes encoding downstream
transcription factors. A MAPK/ERK kinase (MEK) inhibitor reduced ERK phosphorylation in cells with reduced
expression of A-type lamins and emerin. Conclusions: These results provide proof for the hypothesis that
altered expression of emerin and A-type lamins activates ERK signaling, which in turn can cause
cardiomyopathy. General signiﬁcance: ERK is a potential target for the pharmacological treatment of
cardiomyopathy caused by mutations in the genes encoding emerin and A-type lamins.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe nuclear envelope is composed of the nuclear membranes, the
nuclear pore complexes and the nuclear lamina. The nuclear lamina is
a meshwork of intermediate ﬁlament proteins call lamins and is
primarily associated with the inner aspect of the inner nuclear
membrane [1]. Clinical investigations over the past several years have
shown that mutations in the genes encoding lamins and associated
proteins of the inner nuclear membrane cause diverse diseases often
referred to as laminopathies or nuclear envelopathies [2,3].
Emery-Dreifuss muscular dystrophy is characterized by skeletal
muscle weakness and wasting in a humeroperoneal distribution, joint
contractures and dilated cardiomyopathy with conduction defects
[4,5]. The same clinical condition is inherited in an X-linked and an
autosomal manner [4,5]. Mutations in EMD are the cause of X-linked
Emery-Dreifuss muscular dystrophy [6]. EMD encodes emerin, an
integral protein of the inner nuclear membrane that is absent or has
reduced expression in most cases of X-linked Emery-Dreifusskinase; JNK, c-Jun-N-terminal
MAPK/ERK kinase; OD, optical
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l rights reserved.muscular dystrophy [6–8]. Mutations in LMNA cause autosomal
dominant Emery-Dreifuss muscular dystrophy and more rare reces-
sive cases [9,10]. LMNA encodes A-type nuclear lamins [11]. Most
LMNA mutations causing Emery-Dreifuss muscular dystrophy gen-
erate single amino acid substitutions or deletions in A-type lamins but
haploinsufﬁciency can also cause the disease [9,12–14]. While EMD
and LMNA mutations were initially shown to cause the Emery-
Dreifuss phenotype, the same mutations in these genes can cause
cardiomyopathy with different, minimal or no apparent skeletal
muscle involvement [12–18].
The molecular mechanism underlying how deﬁciency in emerin or
A-type lamins causes striated muscle diseases is poorly understood.
We previously identiﬁed abnormal activation of the extracellular
signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK)
branches of the mitogen-activated protein kinase (MAPK) signaling
pathway in hearts of Lmna H222P “knock in” mice, a model of
autosomal Emery-Dreifuss muscular dystrophy [19]. We also observed
activation of the ERK in hearts of emerin-deﬁcient Emd−/y mice, a
model of X-linked Emery-Dreifuss muscular dystrophy [20]. These
studies suggested a connection between abnormalities in proteins of
the nuclear envelope and a cell signaling pathway implicated in the
pathogenesis of cardiomyopathy in tissues. However, data frommodel
cellular systems have been limited to the demonstration that ERK and
JNK are activated in transfected cultured cells overexpressing lamin A
variants in striated muscle diseases [19]. Experiments showing that
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directly activates aMAPK are critical, as positive results would support
the hypothesis that MAPK activation is a primary event rather than a
secondary one occurring as a consequence of cardiomyopathy. We
therefore tested the hypothesis that reducing A-type lamins and
emerin in cultured cells activate ERK.
2. Materials and methods
HeLa cells and C2C12 cells were maintained in a 5% CO2
atmosphere at 37 °C. Cells were cultured in Dulbeco's modiﬁed
Eagle's medium supplemented with 10% calf bovine serum and 0.1%Fig. 1. Knockdown of emerin and A-type lamins using siRNA. (A) Expression of mRNA encod
time quantitative RT-PCR. Bars indicate fold overexpression of the indicated mRNA. Values
expression of GAPDH, emerin and lamin A/C in HeLa cells transfected with siRNA duplexes. A
Gapdh, Emd and Lmna in C2C12 cells transfected with siRNA duplexes, using real-time qua
means±standard deviations for n=3 samples (⁎pb0.05). (D) Immunoblot showing express
Antibody against actin was used as a loading control.gentamicin. One day before transfection, HeLa and C2C12 cells were
trypsinized, diluted with fresh medium without antibiotics and
transferred to 24-well plates. Transient transfection of siRNAs
(50 pM ﬁnal concentration) was carried out using Oligofectamine
(Invitrogen) as recommended by themanufacturer. Cells were assayed
72 h after transfection for HeLa cells and 48 h after transfection for
C2C12 cells. Reduction of expression of targeted genes was conﬁrmed
in at least 3 independent experiments.
For measuring gene expression in cultured cells, media was
removed from cultures reaching 80% and total RNA was extracted
using the Rneasy isolation kit (Qiagen) according to the manufac-
turer's instructions. Adequacy and integrity of extracted RNA wereed by Gapdh, Emd and Lmna in HeLa cells transfected with siRNA duplexes, using real-
are means±standard deviations for n=4 samples (⁎pb0.05). (B) Immunoblot showing
ntibody against actin was used as a loading control. (C) Expression of mRNA encoded by
ntitative RT-PCR. Bars indicate fold overexpression of the indicated mRNA. Values are
ion of GAPDH, emerin and lamin A/C in C2C12 cells transfected with siRNA duplexes.
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ultraviolet absorbance spectroscopy. For real-time RT-PCR, RNA was
reverse transcribed using SuperScript First-Strand Synthesis System
according to the manufacturer's instructions (Invitrogen). Real-time
RT-PCR was performed as previously described [19,20]. Speciﬁcity of
ampliﬁcationwas checked bymelting-curve analysis. Relative levels of
mRNA expression were calculated according to the ΔΔCT method,
normalized by comparison to Gapdh mRNA expression [21].
For immunoblotting, proteins were extracted from cells as
previously described [19,20], separated by SDS-PAGE, transferred to
nitrocellulose membranes and blotted with primary antibodies
against ERK1/2 (Santa-Cruz), pERK1/2 (Cell Signaling), lamin A/C
(Santa-Cruz), emerin (Novocatra), β-actin (Santa-Cruz) and Gapdh
(Santa-Cruz). Secondary antibodies were horseradish peroxidase-
conjugated (Amersham). Recognized proteins were visualized by
enhanced chemiluminescence (ECL—Amersham) and visualized usingFig. 2. Knockdown of emerin and A-type lamins leads to phosphorylation of ERK and increase
of total ERK1/2 and pERK1/2 in HeLa cells transfected with siRNA duplexes. (B) Expression of
time RT-PCR results for c-Jun, Elk1 and Elk4 are shown. Bars indicate the fold overexpression
n=4 samples per group (⁎pb0.05). (C) Representative immunoblot showing expression of tot
downstream genes in ERK pathway in C2C12 cells transfected with siRNA duplexes. Real-tim
of the indicated mRNA normalized to Gapdh. Values are means±standard deviations for n=Hyperﬁlm ECL (Amersham). A signal generated using antibody against
β-actin was used as an internal control to normalize amounts of
protein between immunoblots. Band densities were calculated using
Scion Image software (Scion Corporation) and normalized to the
appropriate total extract to control for protein loading. Data are
reported as means±standard deviations and compared with respec-
tive controls using a two-tailed t test.
For immunoﬂuorescence microscopy, HeLa and C2C12 cells were
grown on coverslips and washed with phosphate-buffered saline.
Cells were ﬁxed for 10 min in methanol at −20 °C. HeLa and C2C12
cells were then incubated at room temperature with antibody against
phosphorylated ERK (pERK) (Cell Signaling). Cells were then washed
with phosphate-buffered saline and incubated with Texas Red
conjugated goat anti-rabbit antibody in PBS (Molecular Probes).
Cells were washed with phosphate-buffered saline and slides
mounted in Mowiol (Santa-Cruz) with 0.1 μg/ml 4′,6-diamidino-2-d expression of downstream genes. (A) Representative immunoblot showing expression
downstream genes in ERK pathway in HeLa cells transfected with siRNA duplexes. Real-
of the indicated mRNA normalized to Gapdh. Values are means±standard deviations for
al ERK1/2 and pERK1/2 in C2C12 cells transfected with siRNA duplexes. (D) Expression of
e RT-PCR results for c-Jun, Elk1 and Elk4 are shown. Bars indicate the fold overexpression
4 samples per group (⁎pb0.05).
Fig. 3. Knockdown of emerin and A-type lamins leads to enhanced nuclear translocation of pERK. (A) Effect of siRNAs on nuclear translocation of pERK in transfected HeLa cells.
Representative photomicrographs are shown for mock transfected cells, cells transfected with siRNA against Gapdh (siRNA Gapdh), Emd (siRNA Emd) and Lmna (siRNA Lmna). Top
panels show labeling of nuclei with 4′,6-diamidino-2-phenylindole (dapi) and bottom panels labeling with antibodies against pERK1/2. Arrowheads show enhanced nuclear
localization of pERK in cells transfected with Emd and Lmna siRNAs. Bar: 10 μm. Bar graph shows percentages of HeLa cells with pERK primarily in the nucleus (see arrowheads for
example). Values aremeans±standard deviations for n=200 cells per group (⁎pb0.05). (B) Effect of siRNAs on nuclear translocation of pERK in transfected C2C12 cells. Representative
photomicrographs are shown for mock transfected cells, cells transfected with siRNA against Gapdh (siRNA Gapdh), Emd (siRNA Emd) and Lmna (siRNA Lmna). Top panels show
labeling of nuclei with 4′,6-diamidino-2-phenylindole (dapi) and bottom panels labeling with antibodies against pERK1/2. Arrowheads show enhanced nuclear localization of pERK
in cells transfected with Emd and Lmna siRNAs. Bar: 10 μm. Bar graph shows percentages of C2C12 cells with pERK primarily in the nucleus (see arrowheads for example). Values are
means±standard deviations for n=150 cells per group (⁎pb0.05).
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an Axiophot microscope (Carl Zeiss). Micrographs were processed
using Adobe Photoshop 6.0 (Adobe Systems).
For colorimetric analysis of ERK1/2 phosphorylation, cells were
cultured for 24 h in the presence of PD98059 (45 μM). ERK1/2
phosphorylation was measured using an enzyme-linked immunosor-
bent assay (SuperArray CASE, ERK1/2 Kit) as per the manufacturer's
protocol. Signal intensities for pERK1/2 or total ERK1/2 were
measured at an optical density (OD) of 450 nm and relative cell
number was assayed in each well (OD of 595 nm). To determine ERK1/
2 phosphorylation, we normalized the pERK1/2 signal ratio (OD450 nm/Fig. 4.MEK inhibitor PD98059 blocks ERK activation in cells with reduced emerin and A-type
of total ERK1/2 and phosphorylated ERK1/2 in HeLa cells transfected with siRNAs against Gap
PD98059 on the expression of total ERK1/2 and phosphorylated ERK1/2 in C2C12 cells trans
linked immunosorbant assay showing effect of the MEK inhibitor PD98059 on the expressi
against Gapdh, Lmna and Emd. Bar graph shows the relative phosphorylation of ERK1/2. Value
to mock treatment, #pb0.05 when compared C2C12 cells with or without addition of PD98OD595 nm) to the total ERK1/2 signal ratio (OD450 nm/OD595 nm). Data
are reported as means±standard deviations and compared with
respective controls using a two-tailed t test.
3. Results
To investigate if reduction of A-type lamins and emerin lead to
activation of ERK signaling, we used a human epithelial cell line
(HeLa cells) and a mouse myogenic cell line (C2C12 cells) and
knocked down targeted genes using siRNA. Total RNAs and proteins
were extracted from HeLa cells cultured without siRNA treatmentlamins. (A) Immunoblot showing effect of the MEK inhibitor PD98059 on the expression
dh, Lmna and Emd. (B) Upper part is an immunoblot showing effect of the MEK inhibitor
fected with siRNAs against Gapdh, Lmna and Emd. Lower part shows results of enzyme-
on of total ERK1/2 and phosphorylated ERK1/2 in C2C12 cells transfected with siRNAs
s are means±standard deviations for n=3 samples per group (⁎pb0.05 when compared
059).
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Gapdh, Emd and Lmna siRNAs were used, corresponding mRNAs
(Fig. 1A) and proteins (Fig. 1B) were reduced by approximately 50%.
In C2C12 cells, total RNA and proteins were extracted after mock
treatment or treatment with Gapdh, Emd and Lmna siRNAs. When
Gapdh, Emd and Lmna siRNAs were used, corresponding mRNAs
(Fig. 1C) and proteins (Fig. 1D) were reduced by approximately 50%.
Treatment with Lmna siRNA also led to modest but reproducible
decreases in cellular emerin (Fig. 1C,D).
To determine if siRNA treatment leads to ERK activation, we ﬁrst
evaluated phosphorylation of ERK isoforms 1 and 2 (ERK1/2).
Immunoblotting with anti-pERK1/2 antibody demonstrated an
increase in pERK1/2 in HeLa cells treated with Emd and Lmna
siRNAs, whereas no signiﬁcant increase was observed in mock
treated cells or cells treated with Gapdh siRNA (Fig. 2A). pERK1/2
activates a series of downstream target genes, including those
encoding c-Jun, Elk1 and Elk4. We analyzed expression of these
transcripts using real-time quantitative RT-PCR. While these indivi-
dual genes were not found to be signiﬁcantly differentially expressed
in mock treated cells or cells treated with Gapdh siRNA (Fig. 2B),
treatment with Emd and Lmna siRNAs leads to a 2-fold to 3-fold
increased expression of c-Jun, Elk1 and Elk4 (Fig. 2B). Abnormal
ERK1/2 activation was also observed in C2C12 cells treated with Emd
or Lmna siRNAs (Fig. 2C). We also found 1.5-fold to 2-fold up-
regulation of c-Jun when C2C12 cells were treated with Emd and
Lmna siRNAs (Fig. 2D). In C2C12 cells, expression of Elk1 and Elk4
was increased approximately 1.5-fold only when treated with Lmna
siRNA but not Emd siRNA (Fig. 2D).
Translocation of pERK1/2 from cytoplasm to nucleus is necessary
for activation of downstream genes. In mock treated HeLa cells and
HeLa cells treated with Gapdh siRNA, pERK was weakly or not
detectable and only approximately 2% of HeLa cells had detectable
nuclear pERK (Fig. 3A). In contrast, treatment with Emd and Lmna
siRNAs induced detectable levels of pERK in the nucleus in
signiﬁcantly more cells (Fig. 3A, arrowheads). Approximately 8% of
HeLa cells treated with Emd siRNA and 10% of HeLa cells treated with
Lmna siRNA had detectable nuclear pERK (Fig. 3A). In mock treated
C2C12 cells and C2C12 cells treated with Gapdh siRNA, pERK was
detectable in less than 1% of nuclei (Fig. 3B). When C2C12 cells were
treated with Emd or Lmna siRNAs, there was a signiﬁcant increase of
cells (approximately 6%) with detectable nuclear pERK (Fig. 3B,
arrowheads). Hence, knocking down expression of Emd and Lmna
induces phosphorylation of ERK, nuclear translocation of pERK and
activation of downstream targets.
MAPK/ERK kinase (MEK) is immediately upstream of ERK in this
branch of the MAPK signaling cascade. MEK phosphorylates ERK to
activate it. We analyzed the effect of the MEK inhibitor PD98059 on
ERK1/2 activity in HeLa and C2C12 cells treated with siRNA against
Emd and Lmna. Cells were cultured with or without PD98059 at a
concentration of 45 μM for 24 h. Immunoblotting with anti-pERK1/
2 antibody demonstrated that the increase in pERK in HeLa and
C2C12 cells treated with Emd and Lmna siRNAs was reduced with
PD98059 added to the culture medium (Fig. 4A and B). Results from
an enzyme-linked immunosorbent assay also conﬁrmed that
PD98059 inhibited activation of ERK1/2 by in the siRNA-treated
cells (Fig. 4B).
4. Discussion
Our previous studies have shown that a missense mutation in
LMNA encoding A-type lamins and loss of emerin activate MAPKs in
the hearts of genetically modiﬁed mice [19,20]. We have analyzed
affected and unaffected tissues in LmnaH222P/H222P mice and found
abnormal activation of genes downstream of ERK only in cardiac and
to a more limited extent in skeletal muscle [19]. We have similarly
demonstrated abnormal activation of ERK and downstream genes inhearts of emerin-deﬁcient mice [20]. We have also demonstrated
previously activation of MAPK signaling in transfected cultured cells
overexpressing lamin A variants with amino acid substitutions found
in subjects with Emery-Dreifuss muscular dystrophy [19]. Here we
showed an aberrant increase of ERK activation and downstream
transcription factors in siRNA-treated HeLa and C2C12 cells with
decreased emerin and A-type lamin expression. It is unclear why in
LmnaH222P/H222P mice ERK activationwas observed only in cardiac and
to a more limited extent in skeletal muscle while in the present study
reduction of A-type lamins and emerin activated ERK in both
myogenic and epithelial cell lines. This could potentially be explained
by the fact that ERK activation is inﬂuenced by the composition of the
extracellular matrix [22–24].
The present results show that decreasing the expression of A-type
lamins and emerin activate MAPKs. We have also previously shown
that expressing lamin A variants that cause cardiomyopathy in
transfected cultured cells activate ERK [19]. These results, along with
evidence of MAPK activation in hearts of LmnaH222P/H222P mice prior to
the presence of clinically detectable cardiomyopathy [19], strongly
suggest that abnormalities in nuclear envelope proteins are a cause of
rather than a consequence of cardiomyopathy. Induced activation of
ERK in hearts of transgenic mice induces a hypertrophic response and
sustained hypertrophy is a leading predictor of heart failure [25].
Hence, the present results provide proof for the hypothesis that
nuclear envelope abnormalities resulting from alterations in emerin
and A-type lamin expression activate ERK that in turn contributes to
the development of cardiomyopathy.
While most of the human LMNA mutations causing cardiomyo-
pathy and skeletal muscle disease are missense, some patients
carry nonsense mutations leading to haploinsufﬁciency [9,12–14].
Therefore, it was physiologically relevant to show that reductions in
A-type lamins, as well as expression lamin variants [19], can
activate ERK. While most mutations in EMD lead to a loss of
emerin, some that cause Emery-Dreifuss muscular dystrophy lead
to stable expression of emerin with amino acid substitutions [6–
8,26,27]. It would be interesting to determine in future studies if
expression of rare emerin variants with amino acid substitutions
found in patients with Emery-Dreifuss muscular dystrophy similarly
activate ERK.
The mechanism responsible for the activation of ERK in cells with
abnormalities in A-type lamins and emerin remains to be determined
experimentally. A-type lamins and emerin interact and depletion of A-
type lamins leads to a redistribution from the inner nuclear
membrane to the bulk endoplasmic reticulum [28–31]. Expression
of some lamin A variants that cause cardiomyopathy and muscular
dystrophy also leads to redistribution of some emerin from the
nuclear envelope to the bulk endoplasmic reticulum [32,33]. Redis-
tribution of emerin to the bulk endoplasmic reticulum is further
associated with proteasome-mediated degradation of emerin [34] and
cellular emerin levels were modestly reduced in the present study in
cells treated with Lmna siRNA. Hence, loss of at least some emerin
from the nuclear envelope along with decreased steady-state cellular
levels may be common phenomena in striated muscle diseases caused
by LMNA and EMD mutations.
Our results have potential practical implications because small
molecule drugs can be used to inhibit ERK. The inhibitor we used,
PD98059, is a selective inhibitor of MEK [35]. It mediates its
inhibitory effects on ERK signaling by preventing phosphorylation
of ERK. In this study, we showed that PD98059 reduces ERK1/2
activity in HeLa and C2C12 cells with reduced A-type lamins and
emerin. We have recently shown that systemic administration of
PD98059 prevents or delays the development of cardiomyopathy in
LmnaH222P/H222P mice [36]. Hence, pharmacological inhibition of ERK
signaling may also be a potential treatment of cardiomyopathy
caused by mutations inducing A-type lamin haploinsufﬁciency or
emerin loss in human subjects.
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